Novel data have revealed that Paneth and DCS cells are also secreting the phospholipases A2 (sPLA2s
) which inhibit Wnt pathway through intracellular activation of Yap1.
showed that bile acids cause surfactant inactivation by enhancing the activity of secretory phospholipase A2 (sPLA2
), a key enzyme in the lung injury pathway .
Abbreviations: NE, nentrophil elastase; sPLA2
, secretory phospholipase A2, Lp-PLA2, lipoprotein-associated phospholipase A2; fMLP, N-formyl-rnethionyllencyl-phenylalanine; NYHA, New York Heart Association; EF, ejection fraction; MI, myocardial infarction; CHD, coronary heart disease; HbAl c, glycollated haemoglobin AIC; CRP, C-reactive protein; MDA, malondialdehyde; ACEI, angiotensin-converting enzyme inhibitors.
Using solid phase chemistry, variants of P-NT.II were designed and examined for inhibitory activity against secretory phospholipase A2 (sPLA2
), a key enzyme involved in the inflammatory pathway, and matrix metalloproteinases (MMPs) that are involved in the remodeling and degradation of the extracellular matrix in rheumatoid arthritis (RA) and cancer.
Edesa Biotech has been notified by the FDA that it may proceed with its clinical investigation of EB01, a novel sPLA2
inhibitor, which Edesa is developing as a potential treatment for chronic allergic contact dermatitis.
PA is then hydrolyzed in the outer leaflet of the plasma membrane by secreted PLA2 (sPLA2
) releasing LPA to the microenvironment .
19 April 2010 - France-based biophamaceutical company Aterovax SA announced today the signing of a three-year, exclusive agreement with SPI-Bio, a French specialist distributor of products and services in drug development, to distribute and sell Aterovax's sPLA2
activity test in Europe to academic and research laboratories for research use.
Las variedades secretorias (sPLA2
) en mamiferos corresponden a los grupos IB, IIA, IIC, IID, IIE, IIF, V, X y XIIA, y de ellas, las pertenecientes a los grupos I, II, V y X son calcio dependientes.
The secretory PLA2 enzyme (sPLA2
) has been characterized and found that two groups, namely, I and II, exist.
12/114,710 entitled 'Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (sPLA2
) inhibitors and sPLA2
inhibitor combination therapies'.
More specifically, the SPA is for the Phase III trial of the company's lead product candidate, A-002, an oral sPLA2
inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.